BPA
SMMT icon

Beacon Pointe Advisors’s Summit Therapeutics SMMT Stock Holding History

Beacon Pointe Advisors’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.79M Buy
94,394
+54,783
+138% +$886K 0.01% 771
2025
Q4 		$693K Buy
39,611
+3,885
+11% +$73.1K ﹤0.01% 953
2025
Q3 		$738K Buy
+35,726
New +$866K 0.01% 872

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Beacon Pointe Advisors's SMMT Position: Q1 2026 in Review

Beacon Pointe Advisors increased its Summit Therapeutics (SMMT) stake by 138% in Q1 2026, buying an estimated $886K and bringing the position to 94,394 shares worth $1.79M. The position accounts for 0.01% of the portfolio, ranked #771.

Beacon Pointe Advisors first reported a position in SMMT in Q3 2025 and has held it in 3 quarters since. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • Beacon Pointe Advisors held 94,394 shares of Summit Therapeutics worth $1.79M as of Q1 2026.
  • Beacon Pointe Advisors bought 54,783 Summit Therapeutics shares in Q1 2026, an estimated $886K.
  • Summit Therapeutics made up 0.01% of Beacon Pointe Advisors's portfolio in Q1 2026, its #771 holding.
  • Beacon Pointe Advisors first reported a position in Summit Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Beacon Pointe Advisors's 13F filing for Q1 2026, filed 15 May 2026.